Before a potential drug candidate reaches the market, lead molecules undergo a battery of tests under rigid regulations. With the launching of Lab21, pharma and biotech companies can now "sub-contract" the pre- and post clinical testing of viral drugs: from lead identification and optimization to pharmacogenetic testing, and even FDA registration.

Dr. Nick Kerton, CEO of Lab21, says:

"We believe that Lab21 has already made significant progress towards the goal of personalised healthcare. Our customers can benefit today from a unique portfolio of tests that allow the characterisation of a virus, the assessment of prospective drug candidates, and the understanding of potential resistance. In addition, we can genotype a trials population, assess their pharmacogenetics, or monitor patients undergoing therapy."Read the press release here. More information about Lab21 here.